Mount Sinai adopts automated data integration for oncology clinical trials

The Mount Sinai Tisch Cancer Center has transitioned its electronic health record (EHR)-to-clinical trial data integration technology from pilot to routine use across its cancer research program. Powered by IgniteData's Archer platform and integrated with Epic, the platform has produced encouraging early results, reducing clinical trial data-entry time by more than half while improving the efficiency and reliability of research data collection.

IgniteData's technology automatically transfers structured clinical information from patients' electronic health records into electronic data capture (EDC) systems used in clinical trials. Since its launch at Mount Sinai in 2025, the system has been activated across all 16 disease groups at the Mount Sinai Tisch Cancer Center and is now incorporated into the startup process for new clinical trials.

Early results show that approximately 70 percent of the data required on electronic case report forms (the standardized forms used to collect information for clinical studies) is populated automatically at each patient visit. Average data-entry time has decreased from 5.5 minutes to 2.5 minutes per visit-a reduction of more than 50 percent. In the data evaluated to date, the system has demonstrated 100 percent data accuracy, with a 0 percent re-query rate.

This is an important step forward in how we conduct clinical research at Mount Sinai. When we can move accurate information directly from the electronic health record into a clinical trial system, our research teams spend less time entering the same information twice and more time focused on caring for patients and advancing research."

Karyn Goodman, MD, MS, Professor and Vice Chair of Clinical Research, Department of Radiation Oncology and Associate Director of Clinical Research, Mount Sinai Tisch Cancer Center

Traditional clinical trial workflows often require research teams to manually transfer information from the EHR into separate EDC systems. This is time-consuming, creates opportunities for transcription errors, and pulls research staff into repetitive administrative work. IgniteData's Archer enables relevant clinical information to flow securely from Epic to EDC systems, reducing duplicate data entry and making information available to research teams more efficiently.

IgniteData CEO, Zach Taft, highlights the value driven with EHR-to-EDC technology. "IgniteData is focused not just on moving data but moving the data that matters. Our commitment to sites and sponsors is to seamlessly transfer the data required for clinical trials in the required formats. This ensures data is consistent, accurate, and tracible – ultimately fueling more efficient clinical trials."

"This technology is making a real difference in the day-to-day work of clinical research teams," said Alex Lieberman-Cribbin, Clinical Trials Manager at the Icahn School of Medicine at Mount Sinai. "By reducing the amount of time spent on manual data entry, we can focus more of our time on study coordination, patient care, and making sure our clinical trials run as efficiently as possible."

The technology is also expanding to support more complex clinical trial data. Mount Sinai is extending the EHR-to-EDC workflow to include real-world medical history, concomitant medications, and efficacy laboratory data. The program has already expanded to support cellular therapies, including CAR-T cell therapy. By incorporating EHR-to-EDC integration into clinical trial startup and expanding its use across disease groups and data types, the Mount Sinai Tisch Cancer Center is making automated data collection an increasingly standard part of its clinical research operations.

The initiative builds on the Mount Sinai Tisch Cancer Center's designation from the NCI as a comprehensive cancer center and Mount Sinai's commitment to advancing research infrastructure, data quality, and access to innovative clinical trials.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study reveals how VEGF-C amplifies lymphangiogenic signaling